by Raynovich Rod | Nov 28, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-3 12/5/25…3:15 PST…EYPT still strong up another 5%;.ADPT down another big 14%-Benziga has a note on a Natera buyout that must be related to drop in ADPT stock. More later but more competition is coming to blood cancers so watch ASH-American Society...
by Raynovich Rod | Nov 13, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/15 Merck buys Cedara for $9.2B for long acting Flu drug. An alternative to vaccines? CDTX up 105% IBB at $164.30 approaching highs of AUG 2021 of $177. Large Cap Biopharma Stocks Lead the Way for Healthcare Investors Biopharma stocks offer growth plus...
by Raynovich Rod | Sep 4, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Small Cap Biopharma Stocks: Momentum Looks Good for Gains Our bellwether ETFs for this group are: Ark Genomic Revolution (ARKG) up 3% 1m and 5% YTD; S&P SPDR Biotech( XBI) up 7.66% 1m and 3.79% YTD. Most of these picks have been screened for analyst ratings (buy...
by Raynovich Rod | Sep 1, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharma Stocks Did Well in August Biopharma stocks offer growth plus dividends.Standouts are ABBV, AZN and GILD. Comeback candidates for 2026: from LLY,REGN and VRTX. Risk remains from tariffs and pushback from Trump Administration policies on drug...
by Raynovich Rod | Aug 18, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-3 8/24 We will focus on Small cap biotechs from our trading list below over the next few weeks now that health care stocks have stabilized. If you have signed uo and are not getting our weekly updates please send an E mail to rod@rayno.com. Thank you....
by Raynovich Rod | Jul 21, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 7/23/25…10:45 a BIOTECH rally continues with ARKG and XBI up on a GREEN SCREEN DAY: Finally — one of our new Trading LIST picks XENCOR (XNCR) shows Momentum at $9.80, undervalued with P/CASh. at 1.5,RSI is now soaring.,one new partnership will...
by Raynovich Rod | Jun 29, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 7/3/25…FIVE Day % winners: AMGN 6.85%, BIIB 4.9%, GILD 3.4%, MRK up 2.66%, PFE 4.7%,REGN 5.06%, VRTX 3.66%. BIOPHARMA OUTperformed many TECH ETFS: QQQ up 1.83%,, SOXX up 1.79%,XLK up 2.35%. BMY up 0.58%.LLY down 1.82%, NVS up 1.3%. NEWs : REGENERON...
by Raynovich Rod | Jun 8, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 6/10/25 …Post ASCO rally: Biotech stocks remained strong from the ASCO Conference with good momentum from SMID caps. ARKG and XBI led the rally. Most mid-caps from our trading list were up with 3+ % gains in: CRMD, CYTK, DNLI, EYPT, ILMN. SLDB, TWST,...
by Raynovich Rod | Jun 2, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-3 ..6/6/25 11:45a. Green screen rally in SMID biotechs ! TECH stocks strong. 330p EDT: I dont know why the SMID biotechs are taking off today but some of it is ETF buying (XBI) here is a shortlist of big movers we hold that are up 3 % + today: ADPT, ABSI,...
by Raynovich Rod | May 27, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 5/3010a EDT….. WHIPSAWED. Changed course again after Trump comments on China roil markets-risk off. Renewed escalation in tensions with China. You have heard the magic word before “uncertainty”. Regeneron continues downward course after...
